Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Cowley

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
European Heart Journal|November 1, 1995
The clinical impact of coronary artery disease; are subjective measures of health status more relevant than laboratory-assessed exercise tolerance?A J Cowley
European Heart Journal|January 1, 1995
Are breathlessness and fatigue in chronic heart failure due to the same pathophysiological abnormality?A J Cowley
Current Opinion in Lipidology|April 1, 1994
Cardiovascular disease and hyperlipidaemiaA J Cowley
American Heart Journal|March 1, 1991
Clinical efficacy of flosequinan in heart failureA J Cowley
Pharmacoeconomics|January 8, 1995
Clinical and economic factors in the treatment of congestive heart failureR Andrews, A J Cowley
Drug Safety|December 1, 1993
Phosphodiesterase inhibitors. Do the risks outweight the benefits?R Andrews, A J Cowley
European Journal of Clinical Pharmacology|January 1, 1991
The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failureH Markus, A J Cowley
Lancet (London, England)|January 21, 1978
Diabetes and therapy with potent diureticsA J Cowley, R S Elkeles
Cardiology|January 1, 1988
Angiotensin-converting enzyme inhibitors--when to use?J R Hampton, A J Cowley
British Heart Journal|September 1, 1994
Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone InvestigatorsA J Cowley, A M Skene
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
European Heart Journal|November 1, 1995
The clinical impact of coronary artery disease; are subjective measures of health status more relevant than laboratory-assessed exercise tolerance?A J Cowley
European Heart Journal|January 1, 1995
Are breathlessness and fatigue in chronic heart failure due to the same pathophysiological abnormality?A J Cowley
Current Opinion in Lipidology|April 1, 1994
Cardiovascular disease and hyperlipidaemiaA J Cowley
American Heart Journal|March 1, 1991
Clinical efficacy of flosequinan in heart failureA J Cowley
Pharmacoeconomics|January 8, 1995
Clinical and economic factors in the treatment of congestive heart failureR Andrews, A J Cowley
Drug Safety|December 1, 1993
Phosphodiesterase inhibitors. Do the risks outweight the benefits?R Andrews, A J Cowley
European Journal of Clinical Pharmacology|January 1, 1991
The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failureH Markus, A J Cowley
Lancet (London, England)|January 21, 1978
Diabetes and therapy with potent diureticsA J Cowley, R S Elkeles
Cardiology|January 1, 1988
Angiotensin-converting enzyme inhibitors--when to use?J R Hampton, A J Cowley
British Heart Journal|September 1, 1994
Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone InvestigatorsA J Cowley, A M Skene
Pageof 11